Markets can ride the COVID-19 vaccine wave for now, but there’s still discovery, development, and the long road to commercialization that lies ahead.
PredictMedix ($PMED.C) made news this year when it came out with its suite of AI technologies that aids institutions and corporations with COVID-19 and work safety detections.
Predict’s suite of AI technologies has seen commercial deployments across the globe, and despite hitting a few snags in its supply chain, the company seems to be on track for growth through the end of Q4 ‘20.
Now, the company has partnered with McGill university where its technology will be researched and developed by Dr. Samira Rahimi, Assistant Professor at McGill University’s Department of Family Medicine, across its three industry verticals – cannabis/alcohol impairment, mental health screening, and COVID-19 detection.
“We are extremely excited about the partnership with Dr. Samira Rahimi’s team. Dr. Rahimi is one of the most recognized AI – healthcare scientists in Canada and we look forward to working with her and her research team for our 3 major verticals.”, said Dr. Rahul Kushwah, COO of Predictmedix Inc.
Speaking of the partnership, Dr. Rahimi commented, “My team and I are looking forward to working with the Predictmedix team. Predictmedix is one of the young and leading AI companies which aims to improve our healthcare system through innovative and cutting-edge digital health technologies.”
I had a chance to speak with Dr. Rahimi about her career, and how she plans to research and develop PredictMedix’s technology. Be sure to keep an eye out for Part 2 in a few weeks, where I follow up with her experiences working with the tech.
